Does rivaroxaban reduce cardiovascular events or death in patients with rheumatic heart disease-associated atrial fibrillation compared to vitamin K antagonist therapy?
In patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonists are superior to rivaroxaban for preventing cardiovascular events or death.
Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
Connolly et al. (Sun,) studied this question.